This site is intended for Healthcare professionals only.

AstraZeneca resolves Faslodex patent litigation in US


AstraZeneca resolves Faslodex patent litigation in US

British drugmaker AstraZeneca Plc said it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG, to resolve Faslodex patent litigation in the U.S.

The company said it agreed to resolve the litigation relating to Sandoz’s generic fulvestrant product, for which it is seeking FDA approval.

Fulvestrant is a type of hormonal therapy drug used to treat breast cancer.

The U.S. Faslodex patents are due to expire in January 2021, with paediatric exclusivity continuing until July 2021.



Source: Reuters
0 comment(s) on AstraZeneca resolves Faslodex patent litigation in US

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted